Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer

Gynecologic Oncology

Volumn 100, Issue 2, 2006, Pages 318-323

  Nicoletto, M O ^a   Falci, C ^a   Pianalto, D ^a   Artioli, G ^a   Azzoni, P ^b   De Masi, G ^c   Ferrazzi, E ^d   Perin, A ^e   Donach, M ^a   Zoli, W ^f  

^a Division of Medical Oncology   (Italy)

^b Ospedale Orlandi   (Italy)

^c S ANTONIO HOSPITAL   (Italy)

^d Ospedale Civile   (Italy)

^e Boldrini Hospital   (Italy)

^f MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

Ovarian cancer; Oxaliplatin; Pegylated liposomal doxorubicin

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANISETRON; OXALIPLATIN; PLATINUM DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE RESISTANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PHLEBITIS; PRIORITY JOURNAL; RECURRENT CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; SURVIVAL RATE;

EID: 30444435539     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.08.020     Document Type: Article

References (17)

1. The ICON and AGO Collaborators Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer; the ICON4/AGO-OVAR-2.2 trial Lancet 361 2003 2099 2106
2. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J. Clin. Oncol. 19 2001 3312 3322
3. M.A. Bookman, H. Malmstrom, G. Bolis, A. Gordon, A. Lissoni, and J.B. Krebs Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin and paclitaxel J. Clin. Oncol. 16 10 1998 3345 3352
4. W. ten Bokkel Huinink, M. Gore, J. Carmichael, A. Gordon, J. Malfetano, and I. Hudson Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer J. Clin. Oncol. 15 1997 2183 2193
5. P.G. Rose, J.A. Blessing, A.R. Mayer, and H.D. Homesley Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinomas: a Gynecologic Oncology Group study J. Clin. Oncol. 16 1998 405 410
6. B. Lund, O.P. Hansen, K. Theilade, M. Hansen, and J.P. Neijt Phase II study of gemcitabine (2′,2′-difluordeoxycytidine) in previously treated ovarian cancer patients J. Natl. Cancer Inst. 86 1994 1530 1533
7. E. Bajetta, A. DiLeo, L. Biganzoli, L. Mariani, F. Cappuzzo, and M. Di Bartolomeo Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease J. Clin. Oncol. 14 1996 2546 2551
8. F. Muggia, J. Hainsworth, and S. Jeffers Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation J. Clin. Oncol. 15 1997 987 993
9. Ovarian Cancer Meta-Analysis Project Cyclophosphamide, doxorubicin, and cisplatin chemotherapy for ovarian carcinoma: a meta-analysis J. Clin. Oncol. 9 1991 1668 1674
10. R.P. A'Hern, and M.E. Gore Impact of doxorubicin on survival in advanced ovarian cancer J. Clin. Oncol. 45 1995 726 732
11. J. Fanning, T.A. Bennett, and R.D. Hilgers Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma Obstet. Gynecol. 80 1992 954 960
12. R.J. West, and S.F. Zweig Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide Eur. J. Gynaecol. Oncol. 18 1997 343 347
13. M.E.R. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, and A. Santoro Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCL (Caelyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann. Oncol. 15 2004 440 449
14. A.N. Gordon, M. Tonda, S. Sun, W. Rackoff On behalf of the Doxil Study 30-49 Investigators Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Gynecol. Oncol. 95 2004 7 8
15. D. Mavroudis, Kouroussis, and J. Kakolyris A phase I study of Caelyx-Oxaliplatin combination in patients with advanced solid tumors Eur. Cancer Conf. 2001 75 [no. 268, ECCO 22 Oct 2001]
16. M. Markman The myth of measurable disease in ovarian cancer (editorial) J. Clin. Oncol. 21 2003 3013 3015
17. A.E. Guppy, and G.J.S. Rustin CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist 7 2002 437 443